Method of thrombocytopathy corection in case of iron-deficient anemia in newborn calves

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 solution in dose 15 mg of iron per 1 kg of live weight of calf body, one time, intramuscularly and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: method makes it possible to stably normalise thrombotic hemostasis in newborn calves with iron-deficient anemia, ensures long-time support of thrombotic hemostasis in optimal mode of functioning, excludes risk of thrombotic complications and assists normal growth and development of calves.

2 ex

 

The invention relates to biology and veterinary medicine, namely to Hematology.

Analogues of the proposed method of correction of thrombocytopathy newborn calves with iron deficiency anemia does not exist.

In the literature there is information on the application of anemia in calves feroglobin (Internal non-infectious diseases of farm animals. Edited Vmenyaemogo. M: "Agropromizdat", 1991. - 576 S.).

In the literature, there are also recommendations for use in calves as immunostimulant of glicerina (N-acetylglucosaminyl-N-acetyl-muramyl-alanyl-D-isoglutamine) (Andronov T.M., Pinegin B.V., goats I.G., Ustinov GI Application immunomodulator of glicerina for the prevention and treatment of animal diseases. Methodical recommendations. Moscow, 2009. - 12 S.).

But never before picopen and its combination with ferroaluminum was not used in newborn calves with iron deficiency anemia with the purpose of relief available to them thrombocytopathy with normalization of platelet aggregation with ADP, collagen, thrombin, ristomycin, hydrogen peroxide, epinephrine -, and combinations of inductors - ADP+adrenaline, adrenaline+collagen, adrenaline+collagen, as well as optimization of intravascular platelet activity, eliminating the risk of development of microthrombi in the vessels, normalizing trophic tissues, growth and development of animals.

the fir of the invention is a complete normalization of platelet aggregation in the newborn calves with iron deficiency anemia.

The essence of the proposed method lies in the fact that for the correction of platelet aggregation in the newborn calves with iron-deficiency anemia is assigned solution feroglobin-75 (1 ml)containing 75 mg of iron per 1 ml of solution at a rate of 15 mg of iron per 1 kg of body weight of the calf at a time, intramuscularly in combination with the feeding of glicerina at 6.0 mg/day in the morning for 6 days (to throw in a 100.0-of 150.0 ml of water, or milk, or colostrum, intended for feeding calves), starting simultaneously with the injection feroglobin.

The method enables stable to normalize platelet hemostasis in newborn calves with iron deficiency anemia in a short period of treatment, taking it to the level typical for healthy calves, on the next day after the treatment, providing a long-term maintenance of platelet aggregation in the optimal mode of operation, allowing to significantly reduce the risk of thrombotic complications and promoting normal growth and development of calves.

Example 1. Newborn calf No. 82 with iron deficiency anemia, the 2nd day of life, body weight 35 kg, were examined in terms of the calf. The calf was taken and examined the blood with the evaluation of the aggregation activity of platelets with a number of inductors (ADP 34,6 with, collagen 28,7 with, thrombin 36,2 C, H2O238,4 with, adrenaline 81,3,ADP+adrenaline 26,9, ADP+collagen 23,8 with, adrenaline+collagen 22,1) and the state of intravascular platelet activity (discocyte 72%, disco echinocyte 15%, ferocity 6%, sphere-echinocyte 6%, bipolar form 1%). The results obtained indicated the presence of calf platelet disorders.

Calves assigned to feroglobin-75 (1 ml) of 7.0 ml single dose, intramuscular injection and feeding diluted to 100.0 ml milk glicerina at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin. This allowed the next day after the termination of the correction completely arrest the thrombocytopathies, to normalize aggregation activity of platelets (ADP 43,2, collagen 37.1, thrombin is 56.4 C, H2O251,0, adrenaline 101,6 with, ADP+adrenaline 36,2, ADP+collagen 32,8 with, adrenaline+collagen 33,4) and intravascular platelet activity (discocyte 83%, disco echinocyte 8%, ferocity 4%, sphere-echinocyte 4%, bipolar form 1%), eliminating the risk of the calf thrombotic manifestations.

Further observation of this calf did not reveal negative dynamics of platelet activity, indicating a lack of risk thrombocytopathy.

Example 2. Newborn calf No. 88 with iron deficiency anemia, the 3rd day of life, weight 28 kg, were examined in terms of the calf. The calf was taken and examined the blood with the assessment of aggregatio the activity of platelets with a number of inductors (ADP 32,6 with, collagen 26,3, thrombin 40,6 s, H2O231,3 with, adrenaline 75,2, ADP+adrenaline 26,8 with, ADP+collagen 20,3 with, adrenaline+collagen 23,0) and the state of intravascular platelet activity (discocyte 66%, disco echinocyte 16%, ferocity 11%, sphere-echinocyte 5%, bipolar form 2%), which allowed him to diagnose the thrombocytopathies with a tendency to hyperaggregation.

Calves assigned to feroglobin-75 5.6 ml single dose, intramuscular injection and feeding diluted in 150,0 ml milk glicerina at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin. This resulted in the following days after the end of the correction completely arrest the thrombocytopathies, to normalize aggregation activity of platelets (ADP 45,2, collagen 39,6 with, thrombin 56,3 s, H2O251,5 with, adrenaline 103,6, ADP+adrenaline 33,7 with, ADP+collagen 33,1, adrenaline+collagen 29,6) and intravascular platelet activity (discocyte 83%, disco echinocyte 7%, ferocity 4%, sphere-echinocyte 4%, bipolar form 2%), eliminating the risk of thrombotic disorders.

Further observation of the calf showed consistently normal platelet activity, excluding his receivenowait risk of thrombosis.

The claimed method is tested on 145 newborn calves with iron-deficiency anemia, showing 100 percent effective in the th correction of iron-deficiency anemia and thrombocytopathy.

The correction method of thrombocytopathy in iron deficiency anemia in newborn calves, including the use of a solution feroglobin-75 at the rate of 15 mg of iron per 1 kg of body weight of the calf intramuscularly once daily in combination with oral application of glicerina at 6.0 mg/day in the morning for 6 days, starting simultaneously with the injection feroglobin.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, one time and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: claimed method makes it possible to avoid vascular complications in newborn calves with iron-deficient anemia, make the herd healthier, reduce murrain, increase volume and quality of obtained meat and milk production, obtain healthy offspring from the animals.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention describes the pyrrolo- and thiazolopyridinium compounds and their pharmaceutically acceptable salts covered by general structural formula I: wherein the values A, B, R1, R2, R3, R4, R5, R6, R7 and R8 are those as presented in cl.1, and a pharmaceutical composition based on the given compound for inhibition of hypoxia-inducible factor (HIF) hydroxylase activity.

EFFECT: there are produced and described new compounds able to modulate hypoxia-inducible factor (HIF) stability and/or activity.

29 cl, 178 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to novel cyanoisoquinoline derivatives of formula I , where R is selected from a group comprising hydrogen and C1-C10 alkyl, R1, R2, R3 and R4 are independently selected from a group comprising hydrogen, halogen, hydroxy, C1-C10 alkyl, substituted with 1-3 halogen atoms or C6-C14 acryl, C6-C14 aryl, -OR7, -SR7 and -SO2R7, where R7 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14 aryl, C3-C10 cycloalkyl, C6-C14 aryl and C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are optionally substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino and C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, and R5 and R6 are independently selected from a group comprising hydrogen and C1-C3 alkyl, or pharmaceutically acceptable salts thereof. The invention also relates to novel cyanoquinoline derivatives of formula II , where R31, R32, R33 and R34 are independently selected from a group comprising hydrogen, hydroxy, halogen, C1-C10 alkyl substituted with 1-3 halogen atoms or with C6-C14 aryl, C6-C14 aryl, -OR37, -SR37 and -SO2R37, where R37 is selected from a group comprising C1-C10 alkyl, C1-C10 alkyl substituted with C6-C14aryl, C3-C10 aryl, C7-C8 heteroaryl containing 1-2 heteroatoms selected from a group comprising N, O and S, where C6-C14 aryl and C7-C8 heteroaryl are substituted with 1-3 substitutes selected from a group comprising halogen, C1-C6 alkoxy, C1-C10 alkyl, C1-C6 dialkylamino C4 heterocyclyl containing 2 heteroatoms selected from a group comprising nitrogen and oxygen, R35 denotes hydrogen or methyl, or pharmaceutically acceptable salts thereof. The invention also relates to specific cyanoisoquinoline compounds, a pharmaceutical composition based on the compound of formula I, a hypoxia-inducible factor (HIF) hydroxylase inhibiting method, a method of treating, preventing or slowing down development of a condition associated with hypoxia-inducible factor (HIF), a condition associated with erythropoietin (EPO), anaemia, based on use of the compound of formula I.

EFFECT: obtaining novel cyanoisoquinoline compounds having useful biological properties.

42 cl, 1 tbl, 54 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to an oral food additive which contains anhydrous ferric pyrophosphate, ferric pyrophosphate monohydrate or nonahydrate and copper citrate. The invention also concerns a method for preparing said additive and using it for balanced iron intake in the patient.

EFFECT: additive under the invention has no unpleasant metal taste even in the absence of flavouring and taste masking ingredients.

19 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to veterinary science. The preparation contains a mixture of colloidal iron, a ligand, zinc, cobalt, selenium and water. The ligand is presented by Triton X-100 (polyethylene glycol mono (tetramethylbutanol) phenyl ester) in the following proportions, mg: colloidal iron (III) 35.0-45.0; Triton X-100 0.20.6; zinc (II) 0.10.3; cobalt (II) 0.050.15; selenium (IV) 0.020.04 and water up to 1000.0.

EFFECT: preparation exhibits high therapeutic and preventive efficacy, low toxicity, keeps dispersion and shows high storage stability.

5 cl, 12 tbl, 13 ex

FIELD: chemistry.

SUBSTANCE: invention relates to pharmaceuticals and medicine and pharmaceutically acceptable derivatives of 2-aminobenzothiazole of general formula 1.

EFFECT: high anti-hypoxic activity and high effectiveness of treatment.

7 cl, 3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely obstetrics, and can be used for treating anaemia in pregnant women. For this purpose, iron preparations are added with Poetam 900 mg/day. The length of the therapeutic course is 3 weeks in moderate severity of anaemia, 6 weeks - in severe anaemia, and 8 weeks - in very severe anaemia.

EFFECT: method provides intensified therapeutic effect ensured by stimulating production of endogenous renal erythropoietin and higher concentration of sulphhydryl groups and lipoproteins in red blood cell membranes with no side effects.

6 tbl, 1 ex

FIELD: medicaments.

SUBSTANCE: present invention provides water-soluble iron-carbohydrate derivative complexes which are suitable for the therapy of iron deficiency states, and the preparation thereof, medicaments comprising them, and the use thereof in the prophylaxis or therapy of iron deficiency states. The medicaments are suitable in particular for parenteral administration. A water-soluble iron-carbohydrate derivative complex obtained from the reaction of an aqueous iron (III) salt solution and (b) an aqueous solution of the product of the oxidation and subsequent derivatization of one or more maltodextrins, wherein the oxidation is carried out with an aqueous hypochlorite solution at a pH value in the alkaline range, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40, and the subsequent derivatization is carried out with a suitable reagent. The process for the preparation of the iron-carbohydrate complex, wherein one or more maltodextrins is oxidized in aqueous solution, at an alkaline pH value, with an aqueous hypochlorite solution, the subsequent derivatization is carried out with a suitable reagent, and the resulting solution is reacted with the aqueous solution of an iron (III) salt, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40.

EFFECT: most derivatised maltodextrin ligands exhibit increased stability towards enzymatic degradation by amylase as compared with underivatised maltodextrin, which can promote retarded and uniform degradation of the iron-maltodextrin derivative complexes according to the invention in the body.

15 cl, 11 tbl, 45 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is haemostimulating medicine, representing immobilised on polymer recombinant erythropoietin, characterised by the fact that recombinant erythropoietin is immobilised by electron-emitting impact by its introduction into solution of low-molecular water-soluble polymer (PEG, polyvinyl pyrrolidone, hydroxyethyl starch with molecular weight 400-4000 Da), preliminarily subjected to impact of ionising irradiation in dose 1-5 Mrad, to final concentration 500-5000 IU in 1 ml of solution. Shown is more expressed specific activity of medication in case of parenteral and per oral intake in comparison to medication "Mircera".

EFFECT: claimed medication does not possess immunogenic properties and does not demonstrate signs of allergenic action.

4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hematology, and can be applied for treatment of hereditary anemias, associated with failure of porphyrine synthesis. For this purpose per orally introduced is 5-aminolevulinic acid or its hexyl ether in doses, which insure compensation of insufficient biosynthesis of 5-aminolevulinic acid by organism.

EFFECT: method insures fast and effective increase of hemoglobin level in treatment of said pathology in experiment.

3 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, one time and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: claimed method makes it possible to avoid vascular complications in newborn calves with iron-deficient anemia, make the herd healthier, reduce murrain, increase volume and quality of obtained meat and milk production, obtain healthy offspring from the animals.

2 ex

FIELD: medicaments.

SUBSTANCE: present invention provides water-soluble iron-carbohydrate derivative complexes which are suitable for the therapy of iron deficiency states, and the preparation thereof, medicaments comprising them, and the use thereof in the prophylaxis or therapy of iron deficiency states. The medicaments are suitable in particular for parenteral administration. A water-soluble iron-carbohydrate derivative complex obtained from the reaction of an aqueous iron (III) salt solution and (b) an aqueous solution of the product of the oxidation and subsequent derivatization of one or more maltodextrins, wherein the oxidation is carried out with an aqueous hypochlorite solution at a pH value in the alkaline range, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40, and the subsequent derivatization is carried out with a suitable reagent. The process for the preparation of the iron-carbohydrate complex, wherein one or more maltodextrins is oxidized in aqueous solution, at an alkaline pH value, with an aqueous hypochlorite solution, the subsequent derivatization is carried out with a suitable reagent, and the resulting solution is reacted with the aqueous solution of an iron (III) salt, wherein when one maltodextrin is used its dextrose equivalent is from 5 to 20 and when a mixture of a plurality of maltodextrins is used the dextrose equivalent of the mixture is from 5 to 20 and the dextrose equivalent of the individual maltodextrins in the mixture is from 2 to 40.

EFFECT: most derivatised maltodextrin ligands exhibit increased stability towards enzymatic degradation by amylase as compared with underivatised maltodextrin, which can promote retarded and uniform degradation of the iron-maltodextrin derivative complexes according to the invention in the body.

15 cl, 11 tbl, 45 ex

FIELD: pharmacology.

SUBSTANCE: invention refers to binuclear cation nitrosyl iron complexes with natural aliphatic thiolyls with general formula [Fe2(SR)2(NO)4]SO4 where R is aliphatic ligands of natural origin.

Also there is proposed method for production of binuclear cation nitrosyl iron complex, nitrogen monoxide donor, inductor of tumor cells apoptosis, application binuclear cation nitrosyl iron complex, pharmaceutical composition and set used for treatment of oncology diseased. The technical result is EFFECT: production of binuclear cation nitrosyl iron complex possessing cytotoxic, apoptotic and NO-donor activity.

15 cl, 2 ex, 4 tbl, 7 dwg

FIELD: pharmacology.

SUBSTANCE: invention refers to binuclear nitrosyl iron complexes with benzazeheterocyclic derivatives with general formula [Fe2(SR)2(NO)4] where R is And where X is NH, S, R1 is lower alkyl. Also there is proposed method for its production, nitrogen monoxide donor, application as oncology drug and for production of oncology drug, pharmaceutical composition and set used for treatment of oncology diseased.

EFFECT: production of binuclear nitrosyl iron complex that is used as an oncology drug with increased effectiveness and decreased toxicity.

15 cl, 3 ex, 4 tbl, 3 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and chemical-pharmaceutical industry, in particular, to medication, applied in case of myocardial infarction and operations on heart in conditions of artificial blood circulation. Water-soluble composition for intravenous introduction, contains ingredients with the following component ratio in wt %: D-glucose 23.40-28.60; potassium chloride 0.14-0.16; potassium salt of L-asparaginic acid 0.81-0.99; semi-magnesium salt of L-asparagenic acid (magnesium L-aspartate) 0.72-0.88; human insulin genetically engineered (in IU/l) 54.00-66.00; dinitrosyl complex of iron (II) with glutathione 0.19-0.23; water for injections - remaining part, with solution pH 7.40.1 at 22C.

EFFECT: application of composition ensures limitation of myocardial infraction size, recovery of metabolic condition of heart at reperfusion, reduces injury of membranes of post-ischemic cardiomyocytes with smaller haemodinamics disorders as compared with traditionally applied medications.

2 dwg, 7 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to use of a tetranitrosyl complex of iron with thiophenol of formula [Fe2(SC6H5)2(NO)4] as an anti-tumour medicinal agent in order to prepare a medicinal agent for treating oncological diseases. The invention also relates to a pharmaceutical composition and a set containing said complex.

EFFECT: invention ensures high efficiency of treatment.

8 cl, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to complex compound of iron with carbohydrate. Complex compound, in addition to iron (III) contains iron (II). Per cent of iron (II) in terms of total amount of iron in complex compound constitutes, at least, 2 wt %. Carbohydrate is selected from group, consisting of natural carbohydrates or synthetic derivatives of carbohydrates, such as starch, hydrolysed starches, dextrins, in particular such as maltodextrin, maltose syrup, glucose syrup, cyclodextins, dextrans, saccharides. Per cent of carbohydrate in terms of complex compound of iron with carbohydrate constitutes from 10 to 80 wt %. Method of obtaining complex compound of iron with carbohydrate includes the following stages. Water solution of suspension of carbohydrate is prepared. After that, iron (III) salts are added at constant pH value within the range from 7 to 13. Iron (III) salt is selected from group, consisting of iron (III) chloride and iron (III) sulfate. Water solution or suspension is heated with further cooling. Formed complex compound of iron with carbohydrate if isolated. Precipitation of complex compound of iron with carbohydrate is performed by addition of one or more alcohols, such as ethanol or propanol. Obtained complex compound is used for production of medication for treatment of iron-deficient anemias, which is well absorbed in organism in case of peroral intake.

EFFECT: iron, included into composition of medication is better resorbed and better tolerated by organism than pure iron preparations.

26 cl, 1 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics, in particular deals with composition with prolonged release of active substance, representing iron source, containing at least one coated granule, said coated granule consisting of particle, which contains said active substance, covered with at least two coats, containing combination of excipients, as well as to method of obtaining it. Claimed compositions can be used for obtaining medication, intended for treatment and/or prevention of iron deficiency and anemia, induced by iron deficiency.

EFFECT: invention provides composition with prolonged release of active substance, possessing high stability and ensuring protection of active substance from oxidation.

30 cl, 2 ex, 3 dwg

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves three intramuscular introduction of ferroglucin 75 mg (1 ml) every 5 days, three intramuscular introduction of phosprenyl by different syringes in different points simultaneously with an iron preparation, 0.12 ml/kg for the first injection, 0.10 ml/kg for the second injection, 0.08 ml/kg for the third injection, and the intramuscular injections of gamavit 0.018 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to prevent vascular complications in newborn calves with anaemia, to optimise microcirculation and tissue trophism, to hasten the growth, to improve a herd, to produce greater amount of meat production, to produce an expected healthy posterity from these animals.

1 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. The method involves prescription of two intramuscular injection of ferroglucin 150 mg (2 ml) every 10 day, three intramuscular injections of phosprenyl in different syringes into different points, 0.12 ml/kg for the first time together with an iron agent, 0.10 ml/kg five days after the first injection of ferroglucin, 0.07 ml/kg for the third time together with the second injection of ferroglucin and intramuscular injections of gamavit 0.020 ml/kg once a day for eight days starting with the first injection of ferroglucin.

EFFECT: method allows to normalise spontaneous erythrocyte aggregation in suckling calves with anaemia, to provide higher additional weights, to reduce mortality and to produce an expected healthy posterity from these animals.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary. Method includes introduction of ferroglucinum-75 in dose 15 mg of iron per 1 kg of live weight of calf intramuscularly, one time and drinking of glicopin in dose 6.0 mg/day is the morning during 6 days, starting simultaneously with injection of ferroglucinum.

EFFECT: claimed method makes it possible to avoid vascular complications in newborn calves with iron-deficient anemia, make the herd healthier, reduce murrain, increase volume and quality of obtained meat and milk production, obtain healthy offspring from the animals.

2 ex

Up!